Drug Trial Radar · NCT06996652
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Aug 1, 2029
Study completion Jan 1, 2030
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Marcus Foundation; National Institute on Aging (NIA); University of Rochester - Center for Health + Technology (CHeT)/Clinical Trials Coordinaton Center (CTCC); The Parkinson Study Group
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Disease Related Pattern (PDRP) will be assessed using change in 18-flurodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging.
Conditions
- REM Sleep Behavior Disorder
Interventions
AdalimumabDrug
40 mg self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
PlaceboDrug
40 mg matching placebo self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Parkinson Disease Related Pattern (PDRP) expressionTime frame: Baseline and Week 96
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California · Not yet recruiting
University of Colorado Anschutz
Aurora, Colorado · Recruiting
Yale Medicine
North Haven, Connecticut · Recruiting
Parkinson's Disease & Movement Disorders Center of Boca Raton
Boca Raton, Florida · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Not yet recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Not yet recruiting
University of Minnesota
Minneapolis, Minnesota · Not yet recruiting
Washington University
St Louis, Missouri · Recruiting
Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas
Las Vegas, Nevada · Not yet recruiting
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire · Not yet recruiting
Weill Medical College of Cornell University
New York, New York · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Not yet recruiting
University of Texas Health Science Center- San Antonio
San Antonio, Texas · Recruiting
Montreal Neurological Institute-Hospital at McGill University
Montreal, Quebec, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.